Hou, Ming-Chih

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer

Gut microbiota and healthHepatocellular Carcinoma Treatment and Prognosis

Cited by 217

Evaluation of the increase in model for end-stage liver disease (ΔMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child–Turcotte–Pugh score

Huo, T.-I., Wu, J.-C., Lin, H.-C., Lee, F.-Y., Hou, M.-C., Lee, P.-C., Chang, F.-Y., & Lee, S.-D. (2005) · Journal of Hepatology

Liver Disease and TransplantationOrgan Transplantation Techniques and Outcomes

Cited by 143

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H. (2020) · Cancers

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 105

Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes

Yen, F.-S., Hou, M.-C., Cheng-Chung Wei, J., Shih, Y.-H., Hsu, C. Y., Hsu, C.-C., & Hwu, C.-M. (2024) · Clinical Gastroenterology and Hepatology

Diabetes Treatment and ManagementLiver Disease and Transplantation

Cited by 73

Schizophrenia and risk of new-onset inflammatory bowel disease: A nationwide longitudinal study

Sung, K., Zhang, B., Wang, H. E., Bai, Y., Tsai, S., Su, T., Chen, T., Hou, M., Lu, C., Wang, Y., et al. (2022) · Alimentary Pharmacology & Therapeutics

Inflammatory Bowel DiseaseSchizophrenia research and treatment

Cited by 38